Abstract The novel antiepileptic drug lacosamide (LCM; SPM927, Vimpat®) has been heralded as having a dualmode of action through interactions with both the voltagegated sodium channel and the neurite outgrowthpromoting collapsin response mediator protein 2 (CRMP2). Lacosamide's ability to dampen neuronal excitability through the voltage-gated sodium channel likely underlies its efficacy in attenuating the symptoms of epilepsy (i.e., seizures). While the role of CRMP2 in epilepsy has not been well studied, given the proposed involvement of circuit reorganization in epileptogenesis, the ability of lacosamide to alter CRMP2 function may prove disease modifying. Recently, however, the validity of lacosamide's interaction with CRMP2 has come under scrutiny. In this review, we address the contradictory reports concerning the binding of lacosamide to CRMP2 as well as the ability of lacosamide to directly impact CRMP2 function. Additionally, we address similarly the contradicting reports regarding the potential disease-modifying effect of lacosamide on the development and progression of epilepsy. As the vast majority of antiepileptic drugs influences only the symptoms of epilepsy, the ability to hinder disease progression would be a major breakthrough in efforts to cure or prevent this debilitating syndrome.
Introduction: Lacosamide as a Novel Anti-Epileptic
Lacosamide (LCM; SPM927, Vimpat®) (R-N-benzyl 2-acetamido-3-methoxypropionamide) is a first in class antiepileptic drug (AED) approved by the United States Food and Drug Administration and the European Medicines Agency for adjunctive treatment of partial-onset epilepsy with or without secondary generalization in adults (for review see [1] ). Lacosamide was first identified as the lead compound in a class of functionalized amino acids demonstrating antiepileptic properties in the maximal electroshock model [2, 3] . Lacosamide reduced seizure activity in the genetically susceptible Frings mouse as well as the hippocampal kindled rat [4] . Additionally, lacosamide demonstrated antiepileptic potential in the 6 Hz psychomotor seizure model of partial epilepsy [5, 6] . The efficacy of lacosamide in these diverse models separated it from currently available antiepileptic drugs. However, lacosamide was unable to ameliorate tonic-clonic seizures associated with subcutaneous administration of picrotoxin, bicuculline, or pentylenetetrazole [6] . Phase III clinical trials evaluated the ability of lacosamide to control partial-onset seizures when used in conjunction with 1-3 other AEDs (for review see [7] ). The proportion of subjects who reported a ≥50 % seizure reduction rate increased from 23 % with placebo to 40 % with 400 mg lacosamide treatment. Unfortunately, seizure freedom remained out of reach, with only 5 of 107 subjects reporting total loss of seizure activity within the 28-day trial period [8] . While improvement was observed with the addition of lacosamide treatment, results were modest. However, the advantage of lacosamide lies within its low potential for drug-drug interactions, allowing it to be combined with almost every class of AED as a concomitant treatment option [7] . While pharmacokinetic studies report a limited impact of age and gender on lacosamide serum levels [9] , no influence on efficacy was identified in clinical trials [10] . Lacosamide treatment was also associated with low incidence of severe adverse advents, with the most commonly reported side effects being dizziness, headache, nausea, and diplopia [11] (For an in-depth review of the clinical value and limitations of lacosamide please see [1] ).
Mechanism of Action
Despite its success in both preclinical and clinical studies, the mechanism by which lacosamide alleviated seizure activity remained unknown [5] . Radioligand displacement studies attempted to identify a target for lacosamide within the central nervous system. While the ability of lacosamide to weakly displace H 3 -Batrachotoxin indicated some level of binding to voltage-gated sodium channels (VGSCs), lacosamide treatment did not affect steady-state gating kinetics or current density [12] . It was ultimately determined that lacosamide reduces excitability through selective enhancement of VGSC slow inactivation [13] . It was hypothesized that this unique method of action would allow for discrimination between steady-state and aberrantly increased levels of firing. Lacosamide derivatives were employed as affinity baits in an attempt to identify any additional targets within the central nervous system [14] [15] [16] . The results of these studies suggested that, aside from the VGSC, lacosamide may also target collapsin response mediator protein 2 (CRMP2). CRMP2, also known as DPYSL2/DRP2, Unc-33, Ulip, or TUC2, is an intracellular phosphoprotein first identified for its role in regulating growth cone extension/retraction [17, 18] . The canonical roles of CRMP2 include its involvement in neurite outgrowth, axon/dendrite specification, neuronal polarity, progenitor proliferation, and radial migration (for review see [18] [19] [20] ). Central to many of these functions is the ability of CRMP2 to regulate microtubule dynamics. Through interactions with the anterograde motor protein kinesin, CRMP2 aids in the transport of tubulin dimers from the soma to distal projections [21] . Additionally, CRMP2 stabilizes the growing end of the microtubule and promotes the inherent GTPase activity of tubulin [22] . The aforementioned processes are governed by the phosphorylation state of CRMP2, whereby phosphorylation by GSK3β, Cdk5, ROCK, CaMKII, or FYN kinase renders CRMP2 inactive, promoting neurite retraction and growth cone collapse [23] [24] [25] [26] [27] [28] [29] [30] [31] . Recent work has uncovered a multitude of additional roles for CRMP2 in neurons including neurodegeneration, cell death, and trafficking control [32] [33] [34] [35] [36] [37] [38] [39] . Indeed, the CRMP2 interactome has expanded to include proteins involved in microtubule dynamics, synaptic assembly, vesicle recycling and endocytosis, neurotransmitter release, and calcium channel regulation (for review see [40] ). Given the number and wide variety of functions and interacting partners, it is not surprising that CRMP2 has been implicated in numerous disease states. Therefore, the potential impact of lacosamide interacting with CRMP2 is substantial.
Does Lacosamide Have a Dual Mode of Action?
Despite the original evidence supporting CRMP2 as a target of lacosamide, the validity of the interaction remains controversial. The first evidence supporting the interaction can be found in the aforementioned preclinical report published by Beyreuther and colleagues [14] . Direct evidence supporting their claims that CRMP2 is a target of lacosamide can be found within a patent application filed by three of the authors: Beyreuther, Stohr, and Freitag [41] . The most convincing data within the application are the radioligand binding studies where they demonstrated competitive and specific binding of [ 14 C]-lacosamide to crude fractions isolated from Xenopus oocytes transfected with CRMP2, as well as rat brain membranes. These studies reported a Kd value lower than 5 μM. Importantly, radioligand binding could be competed off with an excess of cold, unlabeled lacosamide. Additionally, no specific binding was reported from control oocyte fractions not containing CRMP2. Based on these results, along with others supporting the interaction of CRMP2 and lacosamide, the application states the following: "CRMP2 is therefore regarded as a target of lacosamide in the nervous system in epilepsy, pain, essential tremor, dyskinesias, amyotrophic lateral sclerosis, schizophrenia, and other disease conditions" [41] . Soon after, Park and colleagues demonstrated affinitybait capture of CRMP2 by lacosamide in two separate reports [15, 16] . Affinity-bait methods aid in the identification of unknown protein binding partners (Fig. 1) . In these experiments, two additional moieties are added to the ligand in question (i.e., lacosamide), an "affinity bait moiety" (AB) and a "chemical reporter moiety" (CR). Upon binding of the ligand to a potential target, the AB moiety covalently modifies the target creating an irreversible interaction. Binding partners can be identified by in-gel fluorescence of the CR moiety. The addition of the AB and CR groups can potentially modify the ligand; therefore, it is imperative for the final product to mimic the original ligand in functionality. Lacosamide agents containing the AB and CR moieties (lacosamide AB-CR) were determined to provide antiepileptic relief in the MES model similar to that of the parent compound [15, 16] . Soluble mouse brain lysates were incubated with 5 μM of the lacosamide AB-CR compound for 30 min at room temperature and separated using electrophoresis. Proteins captured by the lacosamide AB-CR compound were visualized by in-gel fluorescence of the CR moiety. Reactivity was observed around 62 kDa, which correlates to the size of CRMP2. CRMP2 immunoreactivity was also confirmed at 62 kDa from the samples. To confirm the identity of the 62 kDa protein captured by the affinity bait experiment, the experiment was repeated using a biotinylated lacosamide AB-CR compound. Lacosamide AB-CR/target protein complexes could then be isolated using streptavidin precipitation. Mass spectrometry of the gel-excised 62 kDa band captured by the AB-CR compound confirmed its identity to be CRMP2. Importantly, the capture of CRMP2 by lacosamide AB-CR could be prevented in a dose-dependent manner by excesses of the original lacosamide compound [16] . Other potential targets have since been identified using this method, such as 14-3-3 ζ [42]. However, the impact of this interaction has not yet been determined.
A 2010 report by our laboratory verified the ability to capture CRMP2 with lacosamide affinity bait compounds [43] . Furthermore, in silico docking was used to identify putative binding sites for lacosamide within the CRMP2 protein. The technique uses the known structure of the target protein (CRMP2) to predict the structure of the intermolecular complex when bound to a ligand (lacosamide) (for review see [44] ). A total of 100 runs were carried out over the surface of the CRMP2 protein to yield five pockets capable of coordinating lacosamide binding. Interestingly, it was observed that CRMP2 expression levels could influence the ability of lacosamide to transition voltage-gated sodium channels to the slow-inactivated state in a neuronal cell line. Sitedirected mutagenesis of key residues within the previously identified binding pockets on CRMP2 prevented the impact of CRMP2-overexpression on modulation of VGSC slow inactivation by lacosamide.
While evidence suggested that CRMP2 might be a target of lacosamide, it was unclear if this interaction would impact the function of CRMP2. Calcium dysregulation has been suggested to play a large role in the pathophysiology of various epilepsies [45] . As CRMP2 is a positive regulator of N-type calcium channels, our laboratory sought to determine if acute or chronic lacosamide treatment could impact calcium channel currents. Primary cultured hippocampal neurons were treated with 300 μM lacosamide for 0.5-24 h. Whole cell patch clamp recordings revealed that neither acute nor chronic treatment altered current density or kinetics of activation or inactivation [46] . As the L-type calcium channel currents were inhibited by the presence of nifedipine, currents predominantly represented calcium carried through N-type channels, with a small percentage attributed to P/Q-type channels at this age in culture [47] . Consistent with the previous findings, overexpression of CRMP2 led to a ∼60 % increase in current density, which was not altered by the presence of lacosamide. We then investigated if lacosamide could impact the canonical role of CRMP2 in neurite outgrowth. Sholl analysis was used to measure neurite length and complexity in primary cultured cortical neurons. This technique measures the number of neurites crossing concentric circles (denoted as intersections or branch points) at various radial distances from the cell soma [48] . This consecutive-circles (cumulative intersection) analysis identifies dendritic geometry, ramification abundance, and branching patterns. Overnight application of 300 μM lacosamide led to a ∼30 % decrease in neurite outgrowth, which could not be replicated with the application of other sodium channel inhibitors [49] . Specificity of this outcome was confirmed, as lacosamide was unable to further reduce outgrowth following siRNA knockdown of CRMP2. Concentration-response curves yielded an IC 50 of ∼25 μM, a concentration which was unable to alter sodium channel slow inactivation, suggesting that lacosamide may alter CRMP2 function at concentrations previously considered to be sub-therapeutic. However, the distinct mechanism by which lacosamide impaired CRMP2-mediated neurite outgrowth remained unclear. CRMP2 promotes outgrowth through two separate and distinct mechanisms: (1) linking tubulin dimers to the motor protein kinesin to aid in anterograde transport [21] and (2) enhancing the intrinsic GTPase activity of tubulin [22] . Lacosamide compounds modified to contain affinity bait (AB) and chemical reporter (CR) moieties. Capture and covalent modification of interaction targets occurs at the AB site. Addition of the CR site allows for the isolation (via biotin) or detection (via fluorescence) of the captured complex. Adapted with permission from Park and colleagues [15] The ability of CRMP2 to co-immunoprecipitate tubulin was not affected by upwards of 300 μM lacosamide [49] . Tubulin polymerization, as measured by a turbidimetric assay, is greatly increased in the presence of purified CRMP2 protein. While high concentrations of lacosamide (300 μM) did not alter basal levels of tubulin polymerization, the addition of 3 μM lacosamide was sufficient to prevent increases in polymerization by CRMP2. Previously, our laboratory had created a mutant CRMP2 protein (CRMP2 5ALA ) in which five residues, identified by in silico docking to be the most critical for lacosamide binding, had been mutated to alanines. Lacosamide was unable to block the enhancement of tubulin polymerization by CRMP2 5ALA . Based on these results, we concluded that lacosamide reduces CRMP2-mediated neurite outgrowth by selectively impairing the ability of CRMP2 to enhance tubulin polymerization.
The aforementioned findings supporting a direct interaction between lacosamide and CRMP2 are in contrast to a 2012 report by Wolff and colleagues [50] 3 H] lacosamide. Again, no specific binding was reported. Ultimately, surface plasmon resonance (SPR) was employed to address binding between immobilized CRMP2 and lacosamide. SPR monitors changes in resonance angle of light off a surface as a direct result of changes in the refraction index of the surface. Ligands (lacosamide) interacting the proteins (CRMP2) immobilized onto the surface alters the refraction index of the surface which is detected through changes in the light's resonance angle (for review see [51, 52] ). SPR studies revealed no detectable interaction between immobilized CRMP2 and lacosamide, ranging in concentration from 0.39 to100 μM. However, due to the harsh conditions required for the immobilization process, it is necessary to demonstrate functionality of the protein before lack of binding can be verified. Also, availability of the binding site must also be considered. While the immobilized protein should exist in a variety of confirmations, there is a slight possibility that one orientation is energetically favored, resulting in the majority of the immobilized protein in one confirmation. For these reasons, the use of SPR to confirm lack of binding is considered controversial. Based on the lack of specific binding in this report, the authors infer that any effects of lacosamide on CRMP2, or vice versa, must be indirect in nature. The authors suggest that results gleaned from affinity bait studies do not provide direct evidence that CRMP2 is a target of lacosamide. As the structure of the ligand required modification (addition of AB and CR moieties), the observed interaction may be a result of an altered receptor interaction profile and may not be reflective of interactions between the parent compound and the proposed target.
Recently, our laboratory has employed the novel technique of microscale thermophoresis (MST) to investigate potential binding between lacosamide and CRMP2. MST employs the movement of proteins induced by microscopic temperature gradients to measure interactions between ligands and target proteins. This movement is determined by the entropy of the hydration shell surrounding the target protein. Binding of other proteins, peptides, or small molecules alter the hydration shell, resulting in a change in thermophoretic movement that is visualized as a change in fluorescence [53] (Fig. 2a) . Primary-amine labeled CRMP2 or CRMP2 5ALA was incubated with varying concentrations of lacosamide (0.009-150 μM and 0.03-1,000 μM, respectively). Standard capillaries (Monolith NT Capillaries, NanoTemper) were filled with ∼5 μl of sample mixture, and thermophoresis analysis was performed on a NanoTemper Monolith NT.115 instrument. MST curves were fitted using GraphPad Prism software to obtain relative Kd values. Thermophoresis of labeled CRMP2 was altered by increasing concentrations of lacosamide, indicating an interaction with an apparent Kd value of 1±0.04 μM (Fig. 2b-c) . Thermophoresis of labeled CRMP2 5ALA was not affected by lacosamide, even at concentrations as high as 1 mM (Figs. 2d-f) . The lack of association with CRMP2 5ALA suggests both that the ability of lacosamide to alter thermophoresis of wild-type CRMP2 is not due to non-specific binding and that the interaction between lacosamide and CRMP2 is coordinated by the binding pockets previously identified via in silico docking.
While the MST results provide strong evidence in support of a direct interaction between lacosamide and CRMP2, more research is needed in order to definitively conclude the nature of the interaction, such as irreversibility and dynamics. However, the ability of lacosamide to impair neurite outgrowth and, more specifically, tubulin polymerization induced by wild-type but not mutant CRMP2 provides very strong evidence that lacosamide directly impairs CRMP2 function, irrespective of the nature of the physical interaction. The question remains as to what therapeutic impact this interaction may have. The majority of approved antiepileptic drugs are effective at treating the symptoms of epilepsy, yet cannot be considered "disease modifying" as they do not directly impede disease progression. Partial-onset seizures are associated with acquired epilepsy as they often develop as a direct result of CNS trauma, such as stroke, traumatic brain injury (TBI), infections, or tumors [54] . Unfortunately, the mechanisms underlying epileptogenesis, particularly in acquired epilepsies, are not well understood.
Therapeutic Potential of an Interaction Between CRMP2 and Lacosamide
One hallmark of acquired epilepsy is the presence of a potentially months-long asymptomatic latent period between the instigating injury and the development of spontaneous recurrent seizures. This latent period provides a unique opportunity for prophylactic intervention if therapeutic targets were to be identified. Animal models have revealed significant morphological changes occurring during this period, which may be attributed to the development of epilepsy. One of the more striking changes is aberrant sprouting of axons in response to injury, which has been observed both in the hippocampus and the neocortex in a variety of models [55] [56] [57] . Sprouting of injured axon fibers is associated with the formation of recurrent excitatory circuits [58] , which directly contribute to the development of spontaneous seizure activity [59, 60] . Robust axon sprouting and elongation have also been observed following in vitro lesion of axon collaterals and is sufficient to induce hyperexcitability and increased polysynaptic, epileptiform burst discharges [61] . A previous study of postmortem tissue samples from patients with mesial temporal lobe epilepsy observed a decrease in a 55 kDa band associated with CRMP2, without a change in the higher molecular weight band [62] . It is now known that as the two splice variants of CRMP2 are expressed at 75 and 64 kDa [63] , the 55 kDa band likely reflects a calpain-mediated breakdown product of CRMP2 [64] . What will be of particular interest are potential changes in phosphorylation state within the hippocampus of temporal lobe epilepsy patients, as the ability of CRMP2 to mediate neurite outgrowth is regulated via numerous phosphorylation events [23, 25-27, 29-31, 65, 66] . Indeed, changes in phosphorylation of CRMP2 have been observed following traumatic events often associated with the development of temporal lobe epilepsy, such as hypoxiaischemia and TBI [67, 68] . Interestingly, recent work has linked the sprouting of mossy fibers in the hippocampus following status epilepticus with CRMP2 [69] . The ability of lacosamide to target not only sodium channel activity, but CRMP2-mediated synaptic reorganization as well, may afford efficacy in the prevention of epileptogenesis, where so many classical antiepileptics have failed. However, the antiepileptogenic potential of lacosamide relies heavily on the assumption that the relationship between aberrant sprouting and epileptogenesis is causal in nature.
Work by Brandt and colleagues demonstrated that lacosamide treatment could hinder the progression of kindling [70] , a model often used to investigate mechanisms of epileptogenesis (for review see [71] ). As the majority of AEDs are not disease modifying, they do not alter kindling acquisition (for review see [72] ). Rats were kindled by once-daily stimulation of the amygdala 0.5 h following intraperitoneal injection of 3, 10, or 30 mg/kg lacosamide. Both the severity of seizures and the duration of after-discharges elicited by each current injection were decreased in animals treated with 10 or 30 mg/kg lacosamide. Additionally, lacosamide treatment led to a ∼90 % increase in the number of stimulations required for kindling. In fact, while all of the vehicle-treated rats were successfully kindled, kindling in the 10 and 30 mg/kg treatment groups was unsuccessful in 2/10 and 3/10 rats, respectively. To determine if the effect of lacosamide was long-lasting, after 22-23 days of stimulation, rats were allowed a 2.5-month washout period, during which they received no current injections. All rats could be rekindled within four stimulations, regardless of prior lacosamide treatment. This outcome can be explained in a variety of ways. Of the rats used for the washout experiments, 7/10 lacosamide-treated rats and 10/10 vehicle-treated rats had reached kindled status, which by definition insinuates that all rats underwent class V seizures in response to the same current injection. Therefore, as the seizure severity was relatively conserved across treatment groups in the presence of treatment, differences following a treatment-free washout period were unlikely. For this reason, previous work involving washout periods following amygdala stimulations excluded animals which had reached kindled status prior to washout [73] . In these studies, which identified potential antiepileptogenic properties of the AED levetiracetam, the rate of kindling following washout was slower in previously exposed animals. Once kindling was obtained, however, focal seizure threshold was not different from controls. Therefore, it is possible that while the kindling model provides a framework for antiepileptogenic intervention, once kindling status has been reached the opportunity for prophylaxis may have passed. Alternatively, as lacosamide is now known to lower excitability by enhancing sodium channel slow inactivation, treatment directly prior to stimulation may have simply dampened the response to the current injections, thereby impeding the kindling process.
Aside from kindling, models involving spontaneous recurring seizures following sustained status epilepticus (SE) in rodents have been extensively used to evaluate antiepileptogenic potential of therapeutic agents. Animals were given a single dose of lacosamide, 10 min following initiation of perforant path stimulation, which lasted 30 min. Lacosamide treatment was associated with a dose-dependent decrease in the number of spontaneous recurrent seizures (SRS) 6 weeks following induction of status epilepticus [74] . As the development of SRS is dependent upon successful, sustained status epilepticus, it is possible that the reduction of seizures is a direct result of lacosamide interfering with the induction process. Therefore, a second group of animals received lacosamide treatment 40 min following perforant path stimulation. While all of the vehicle-treated animals demonstrated SRS, they were only observed in three of nine lacosamidetreated animals. Interestingly, of the animals that did develop SRS, there was no difference in the number of seizures across groups, suggesting that the development of SRS may be an all or nothing process. That late lacosamide treatment was able to prevent the development of SRS in six of nine animals suggests that lacosamide may have some antiepileptogenic potential. Although its direct role in epileptogenesis has not been confirmed, extensive mossy fiber sprouting occurs following SE and has been linked to changes in CRMP2 function [69] . Our laboratory recently employed the undercut (neocortical isolation) model of posttraumatic epileptogenesis to explore the ability of lacosamide to alter CRMP2-mediated changes in excitatory connectivity [49] . In this model of posttraumatic epileptogenesis, axon sprouting has been demonstrated by morphological reconstruction of axons of the layer V pyramidal neurons [55] and by functional mapping of excitatory synaptic connectivity using laser scanning photostimulation of caged glutamate [58] . Animals received daily lacosamide treatments for 1 week following surgery, upon which time the animals were allowed to recover an additional week. While field potential recordings did not reveal a difference in the frequency of evoked epileptiform events, the mean amplitude of the recordings was significantly lower in lacosamide-treated animals. Importantly, electrophysiological recordings from layer V pyramidal neurons revealed a decrease in the frequency of spontaneous excitatory postsynaptic currents. A decrease in frequency without a change in the amplitude or kinetics (rise time, decay time, constant, and ½ width of events) is indicative of a decrease in the number of synaptic connections. Indeed, glutamate uncaging studies demonstrated a decrease in excitatory connectivity following lacosamide treatment. As animals had undergone a 1-week washout period prior to all recordings, these results suggest that lacosamide may have had a disease-modifying effect following neocortical isolation.
As previously mentioned, traumatic brain injury is a common instigator of acquired epilepsy. Mice receiving closedhead TBI were treated with lacosamide 30 min following injury and continuing twice daily for 3 days. Lacosamide treatment was associated with a decrease in neuronal injury that was correlated with a delay in the expression of proinflammatory mediator genes and reduced microglial activation [75] . Lacosamide-treated mice demonstrated improved function in both the rotorod and Morris water maze paradigms. Interestingly, contrary to previous reports that CRMP2 activity is important in mossy fiber sprouting and that lacosamide can impact CRMP2 function, the emergence of mossy fiber projections into the inner molecular layer was not altered by lacosamide treatment. However, mossy fiber sprouting is viewed as a progressive process and is typically measured in much later stages following injury. It would be interesting to extend treatment well into the latent period when mossy fiber sprouting is at its highest. In a recent study of rats exposed to the lateral fluid percussion model of TBI, however, lacosamide given at 30 min postinjury and continued at 8-h intervals for 3 days had no effect on neuroscore, beam walking, or water maze performance [76] . Furthermore, histological analysis revealed no difference in the extent of neurodegeneration, axonal injury, or hilar neuron loss within the hippocampus of lacosamide-treated rats compared to vehicle treatment. Recently, Licko and colleagues sought to expand previous reports on the anti-epileptogenic potential of lacosamide following status epilepticus [77] . To avoid any possible interference with the induction of sustained SE, lacosamide treatment began following its cessation and was continued for 23 days. On the molecular level, many hallmarks associated with status epilepticus were altered by lacosamide treatment. Chronic lacosamide treatment prevented both neurogenesis of granule neurons as well as cell loss within the piriform cortex and CA1 region of the hippocampus yet did not impede the aberrant migration of neurons into the hilus. Unfortunately, the extent of mossy fiber sprouting was not determined in this report. However, lacosamide treatment was associated with a decrease in the number of SE-induced persistent basal dendrites present in the hilar region. Despite the impact on molecular changes induced by SE and contrary to previous reports, lacosamide treatment did not successfully prevent the development of SRS. Additionally, latency to first seizure and the frequency of spontaneous seizures were not attenuated by chronic lacosamide treatment [77] . While the treatment paradigm was somewhat unorthodox, combining oral administration and continuous infusion via osmotic minipump, it is unlikely that this would account for the lack of efficacy in preventing the development of spontaneous seizures. In light of all the aforementioned work in vivo, it is difficult to determine whether lacosamide is antiepileptogenic in nature.
Combined in vivo results suggest that lacosamide may have potential as a disease-modifying AED; however, more work is needed in two critical areas: (1) It is necessary to determine whether lacosamide prevents aberrant sprouting, such as that of mossy fibers within the hippocampus, in multiple of models of acquired epilepsy. While it is likely that there are common mechanisms involved in aberrant sprouting induced by different insults, even slight disparities may account for incongruous reports using different models. It is important not to dismiss the therapeutic potential of a compound based on the results from one model alone, especially as it is unclear which model most directly mimics the human condition. (2) Is preventing aberrant sprouting sufficient to prevent epileptogenesis? The relationship between epileptogenesis and circuit reorganization is still highly debated. In theory, the formation of recurrent excitatory circuits should increase excitability and decrease the threshold for spontaneous epileptiform events [78] . However, recent work by the Buckmaster group has demonstrated the ability to attenuate mossy fiber sprouting with rapamycin without impacting seizure frequency following status epilepticus in mice [79] . While the results suggest a disconnect between mossy fiber sprouting and epileptogenesis, the authors advise that rapamycin, at the doses required to completely block mossy fiber sprouting, has many other effects. According to the authors, some of these effects may be pro-epileptogenic in nature, thereby canceling out any potential antiepileptogenic effect that the prevention of mossy fiber sprouting may carry. Therefore, we still cannot definitively identify the exact role of mossy fiber sprouting without more selective means.
Additionally, as CRMP2 is also involved with important developmental processes such as neuronal migration and polarity, we must also consider the potential negative impact of targeting CRMP2 in pediatric patients. Despite these concerns, however, the safety profile of lacosamide in children is reminiscent of that in adults [80] . In fact, lacosamide has recently shown promising potential in the treatment of refractory focal epilepsy with high tolerability in two separate reports utilizing patient populations with a median age of 13.9 and 2.7 years [81, 82] . Nevertheless, limited data is available for the long-terms effects of lacosamide treatment in pediatric patients or those exposed prenatally [83] . Given the role of neurite outgrowth in neuronal plasticity of particular interest will be the long-term impact of lacosamide treatment on learning and memory.
Conclusion
Here, we have addressed two controversial issues surrounding the novel antiepileptic drug lacosamide. First, is CRMP2 a bona fide target of lacosamide? Second, does lacosamide's proposed dual mode of action provide disease-modifying properties? Unfortunately, direct answers exist for neither of these issues. However, new data presented here of a specific association between lacosamide and CRMP2 in solution, in combination with previous reports of a direct impact on CRMP2 function, provide strong evidence in support of a direct interaction between lacosamide and CRMP2. Future work should seek to address the disease-modifying potential of lacosamide. Given the two distinct mechanisms through which lacosamide may impact epileptogenesis (hyperexcitability via the VGSC and circuit reorganization via CRMP2), it would be of great interest to dissect out the individual importance of each on the full mechanism of action of lacosamide (Fig. 3) . Additionally, understanding the molecular and mechanistic framework for lacosamide's actions on CRMP2 will consolidate the involvement of CRMP2 as a potentially important player in neuropathology and as a novel drug target for epilepsy. Fig. 3 Mechanisms through which lacosamide (LCM) may provide disease-modifying effects. Enhancement of sodium channel slow inactivation leads to a decrease in the fraction of available voltage-gated sodium channels. Through this mechanism, LCM is able to hinder epileptiform activity. Inhibition of CRMP2-mediated tubulin polymerization may attenuate the aberrant circuit reorganization commonly observed within the epileptic hippocampus and neocortex. While the exact contribution of this reorganization to epileptogenesis is not yet fully understood, it is possible that the two functions of lacosamide may provide the ability to affect disease progression
